Innoviva FY2026 Earnings Forecast Boosted by HC Wainwright

Innoviva logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS forecast for Innoviva to $2.37 from $2.30, and estimates $2.30 EPS for FY2027.
  • Innoviva’s latest quarterly results missed expectations: it reported a $1.03 per-share loss versus consensus EPS of $0.52, while revenue of $106.12 million came in below the $115.31 million estimate.
  • Analyst sentiment remains positive overall, with a Moderate Buy consensus rating and a $39 average price target; shares opened at $18.49, down 2.8%.
  • Five stocks we like better than Innoviva.

Innoviva, Inc. (NASDAQ:INVA - Free Report) - Research analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of Innoviva in a research report issued on Friday, November 13th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will earn $2.37 per share for the year, up from their previous estimate of $2.30. The consensus estimate for Innoviva's current full-year earnings is $1.52 per share. HC Wainwright also issued estimates for Innoviva's Q2 2027 earnings at $0.59 EPS and FY2027 earnings at $2.30 EPS.

Innoviva (NASDAQ:INVA - Get Free Report) last released its earnings results on Wednesday, November 4th. The biotechnology company reported ($1.03) EPS for the quarter, missing the consensus estimate of $0.52 by ($1.55). The firm had revenue of $106.12 million during the quarter, compared to analyst estimates of $115.31 million. Innoviva had a net margin of 44.13% and a return on equity of 22.91%.

Several other equities analysts have also recently issued reports on INVA. Cantor Fitzgerald decreased their price target on Innoviva from $36.00 to $34.00 and set an "overweight" rating on the stock in a report on Friday, August 7th. Weiss Ratings raised Innoviva from a "hold (c+)" rating to a "buy (b)" rating in a report on Monday, November 9th. Oppenheimer cut their target price on shares of Innoviva from $35.00 to $34.00 and set an "outperform" rating on the stock in a research report on Thursday, November 5th. Zacks Research raised shares of Innoviva from a "strong sell" rating to a "hold" rating in a research note on Monday, August 31st. Finally, Wall Street Zen lowered shares of Innoviva from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $39.00.

Get Our Latest Research Report on INVA

Innoviva Trading Down 2.8%

Shares of INVA opened at $18.49 on Tuesday. The company has a quick ratio of 14.58, a current ratio of 15.44 and a debt-to-equity ratio of 0.23. Innoviva has a 12-month low of $18.41 and a 12-month high of $25.15. The firm has a market capitalization of $1.31 billion, a PE ratio of 9.29, a price-to-earnings-growth ratio of 4.15 and a beta of 0.38. The stock's fifty day simple moving average is $20.64 and its 200-day simple moving average is $21.85.

Institutional Investors Weigh In On Innoviva

A number of institutional investors have recently made changes to their positions in the stock. Fortitude Family Office LLC acquired a new position in Innoviva in the third quarter valued at about $25,000. Parallel Advisors LLC grew its position in shares of Innoviva by 82.8% during the 1st quarter. Parallel Advisors LLC now owns 1,179 shares of the biotechnology company's stock worth $27,000 after buying an additional 534 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of Innoviva during the 2nd quarter worth about $30,000. Allworth Financial LP acquired a new position in shares of Innoviva during the 2nd quarter worth about $42,000. Finally, Versant Capital Management Inc increased its stake in shares of Innoviva by 96.5% in the 3rd quarter. Versant Capital Management Inc now owns 1,916 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 941 shares during the last quarter. 99.12% of the stock is owned by institutional investors and hedge funds.

About Innoviva

(Get Free Report)

Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.

Further Reading

Earnings History and Estimates for Innoviva (NASDAQ:INVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Innoviva Right Now?

Before you consider Innoviva, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innoviva wasn't on the list.

While Innoviva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines